InvestmentJun 23, 2026, 08:21 AM
SRX Global Invests in ARMR Sciences for Fentanyl Countermeasure
AI Summary
SRX Global, Inc. announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company. ARMR Sciences is developing medical countermeasures against synthetic drugs such as fentanyl, with its lead product, ARMR-100, recently demonstrating a successful anti-fentanyl immune response and favorable safety data in humans. This investment supports ARMR-100's development as a potential long-lasting preventive medication, with the next phase of trials expected to begin later in 2026.
Key Highlights
- SRX Global, Inc. announced a strategic investment in ARMR Sciences.
- ARMR Sciences is a clinical-stage biodefense company developing countermeasures against synthetic drugs like fentanyl.
- ARMR's lead product, ARMR-100, successfully generated an anti-fentanyl immune response in humans.
- ARMR-100 showed favorable safety data in its Phase 1/2 clinical trial.
- The product aims to be a long-lasting preventive medication against fentanyl, enduring 6-12 months.
- The next phase, evaluating protection against fentanyl, is on track to begin later in 2026.
Price Impact
More from SRXH